Zepbound is FDA-approved for two uses: chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity, and moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The active ingredient is tirzepatide, a once-weekly subcutaneous dual GIP and GLP-1 receptor agonist made by Eli Lilly. Zepbound is intended to be used alongside a reduced-calorie diet and increased physical activity, not as a stand-alone solution.
FDA-Approved Indications for Zepbound
Chronic Weight Management
Zepbound was first approved by the FDA in November 2023 for chronic weight management. The labeled population is adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. The medication is meant to be used in combination with a reduced-calorie diet and increased physical activity, per the Zepbound prescribing information.
Obstructive Sleep Apnea
In December 2024, the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity, making it the first medication ever labeled for OSA in this population. The approval was based on the SURMOUNT-OSA trials, which showed that tirzepatide significantly reduced the apnea-hypopnea index alongside weight loss. The FDA’s announcement notes that Zepbound is intended for use with a reduced-calorie diet and increased physical activity in this indication as well.
How Zepbound Works
Tirzepatide is a 39 amino acid peptide that activates two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Activation of these receptors slows gastric emptying, increases satiety, reduces appetite, and improves insulin secretion in response to meals. The dual mechanism is thought to drive the larger weight loss seen with tirzepatide compared with semaglutide-only agents. For background on the broader role of these therapies in metabolic disease, see our treatment hub.
Typical Dose Schedule
| Weeks | Dose | Purpose |
|---|---|---|
| 1 to 4 | 2.5 mg weekly | Initiation; tolerability only |
| 5 to 8 | 5 mg weekly | First maintenance option |
| 9 to 12 | 7.5 mg weekly (titration) | Stepwise increase as needed |
| 13 to 16 | 10 mg weekly | Second maintenance option |
| 17 to 20 | 12.5 mg weekly (titration) | Stepwise increase as needed |
| 21 and beyond | 15 mg weekly | Highest maintenance option |
Approved maintenance doses are 5, 10, and 15 mg per week. Titration is intended to reduce gastrointestinal side effects. If a higher dose is not tolerated, your clinician may extend the time at a lower step or stay at a maintenance dose that you tolerate well.
What the SURMOUNT Trials Showed
The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults without type 2 diabetes who had a BMI of 30 or higher (or 27 or higher with a weight-related comorbidity). At 72 weeks, mean percentage change in body weight was approximately minus 15 percent at the 5 mg dose, minus 19.5 percent at 10 mg, and minus 20.9 percent at 15 mg, compared with minus 3.1 percent on placebo. Improvements in waist circumference, blood pressure, lipids, and glycemic markers were also observed. SURMOUNT-2 evaluated tirzepatide in adults with both obesity and type 2 diabetes, and SURMOUNT-OSA addressed sleep apnea outcomes.
Common and Serious Side Effects
The most frequently reported adverse reactions in clinical trials of Zepbound include:
- Nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia
- Decreased appetite and early satiety
- Injection-site reactions such as redness or mild swelling
- Fatigue, particularly during titration weeks
- Hair thinning in some patients during rapid weight loss
Serious but less common risks listed in the prescribing information include acute pancreatitis, gallbladder disease, acute kidney injury from dehydration, severe hypersensitivity reactions, hypoglycemia (especially when combined with insulin or sulfonylureas), diabetic retinopathy complications, and acute injury related to suicidal behavior or ideation that should be monitored. The label also carries a boxed warning regarding thyroid C-cell tumors based on rodent studies. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Who Should Avoid Zepbound
- People with a personal or family history of medullary thyroid carcinoma or MEN 2.
- People with severe hypersensitivity to tirzepatide or any inactive ingredient.
- People who are pregnant; tirzepatide is not recommended in pregnancy, and a washout period before conception is advised.
- People with a history of pancreatitis should discuss the risk-benefit balance carefully with their clinician.
If you have prediabetes or elevated A1C levels and are evaluating treatment options, ask your prescriber whether Mounjaro (the diabetes-labeled tirzepatide) or Zepbound is the appropriate choice for your situation.
The Bottom Line
Zepbound’s labeled uses today are chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity, both used together with diet and increased physical activity. The medication delivered approximately 15 to 21 percent average weight loss in late-stage trials and meaningful improvements in cardiometabolic markers. The benefit comes with a defined side effect profile that is mostly gastrointestinal and a small set of serious risks that warrant monitoring. Decisions about whether and how to start Zepbound belong with you and your prescriber.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
